Meeting
2015 ASCO Annual Meeting
Pazopanib for soft tissue sarcoma (STS) in the first- line setting with denosumab.
Authors
Hiroyuki Narahara
Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan
Hiroyuki Narahara , Kayo Yasuda , Kaori Morita , Hitoshi Matsumoto , Yuichi Yasunaga , Yoshiaki Inui , Sumio Kawata , Katsuhito Takahashi , Satoshi Teraoka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 33, 2015 (suppl; abstr 10567)
DOI
10.1200/jco.2015.33.15_suppl.10567
Abstract #
10567
Poster Bd #
211
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas.
First Author: Kwai Han Yoo
Poster
2020 Genitourinary Cancers Symposium
Outcomes of adult urogenital sarcomas: Analysis of surveillance, epidemiology, and end results (SEER) database 2004 to 2015.
First Author: Snigdha Nutalapati
Poster
2017 ASCO Annual Meeting
Rates of survival throughout the years in soft tissue sarcoma with synchronous metastases: Results of a population-based study.
First Author: Melissa Vos
Poster
2016 ASCO Annual Meeting
Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study—NCT01692496.
First Author: Claudia María Valverde